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Abstract
PURPOSE: Tumor endothelial cells express vascular endothelial growth factor receptor 2 (VEGFR-2). VEGF can direct
toxins to tumor vessels through VEGFR-2 for antiangiogenic therapy. This study aimed to selectively damage the
VEGFR-2–overexpressing vasculature of pancreatic cancer by SLT–VEGF fusion protein comprising VEGF and the
A subunit of Shiga-like toxin which inhibits protein synthesis of cells with high VEGFR-2 expression. EXPERIMENTAL
DESIGN: Expression of VEGF and VEGF receptors was evaluated in human pancreatic cancer cells (AsPC-1, HPAF-2)
and in normal human endothelial cells (HUVEC) by reverse transcription–polymerase chain reaction. Cells were treated
with SLT-VEGF (0.1-10 nM), and cell viability, proliferation, and endothelial tube formation were assessed. Orthotopic
pancreatic cancer (AsPC-1, HPAF-2) was induced in nude mice. Animals were treated with SLT-VEGF fusion protein
alone or in combination with gemcitabine. Treatment began 3 days or 6 weeks after tumor induction. Primary tumor
volume and dissemination were determined after 14 weeks. Microvessel density and expression of VEGF and VEGF
receptors were analyzed by immunohistochemistry. RESULTS: SLT-VEGF did not influence proliferation of pancreatic
cancer cells; HUVECs (low-level VEGFR-2) reduced their proliferation rate and tube formation but not their viability.
SLT-VEGF fusion protein reduced tumor growth and dissemination, increasing 14-week survival (AsPC-1, up to 75%;
HPAF-2, up to 83%). Results of gemcitabine were comparable with SLT-VEGF monotherapy. Combination partly
increased the therapeutic effects in comparison to the respective monotherapies. Microvessel density was reduced
in all groups. Intratumoral VEGFR-2 expression was found in endothelial but not in tumor cells. CONCLUSIONS:
SLT-VEGF is toxic for tumor vasculature rather than for normal endothelial or pancreatic cancer cells. SLT-VEGF treat-
ment in combination with gemcitabine may provide a novel approach for pancreatic cancer.
Neoplasia (2010) 12, 797–806
Introduction
Adenocarcinoma of the exocrine pancreas is the fifth leading cause of
cancer-related death in Western countries. The estimated overall 5-year
survival rate of less than 5% is due to the tumor’s propensity toward
aggressive growth, early metastasis, and resistance to cytotoxic agents
and radiation.More than 80% of patients are diagnosed with pancreatic
cancer at a locally advanced ormetastatic stage, which excludes a curative
surgical resection [1]. New therapeutic approaches based on the biologic
characteristics of this disease may improve response rates and survival.
One promising approach is the inhibition of angiogenesis. Like all solid
neoplasms, pancreatic cancer depends on the process of angiogenesis,
the formation of tumor blood vessels, for both local and metastatic
growth beyond the size of a few cubic millimeters [2]. Inhibition of
angiogenesis is an attractive target for tumor therapy because it theo-
retically offers the hope of long-term control of neoplasm progression
[3]. Among the identified proangiogenic regulators, vascular endothelial
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growth factor (VEGF; a.k.a. VEGF-A) and its two tyrosine kinase re-
ceptors, the fms-like tyrosine kinase receptor (Flt1, VEGFR-1) and the
kinase insert domain-containing receptor (KDR/FLK1, VEGFR-2),
have been identified as key mediators of the regulation of pathologic
blood vessel growth and maintenance [4]. VEGF induces endothelial
cell proliferation and enhances vascular permeability [5]. Previous
studies have shown that VEGF is overexpressed in human pancreatic
cancer [6–8]. Moreover, a high expression of VEGF was associated
with liver metastasis and a poor prognosis for patients with ductal pan-
creatic adenocarcinoma [9,10]. In most epithelial tumors, including
pancreatic cancer, VEGFR-1 and VEGFR-2 are expressed almost ex-
clusively on endothelial cells, and there is evidence that endothelial
cells at sites of angiogenesis express significantly higher numbers of
VEGFR-2—the key proangiogenic receptor—than quiescent endothe-
lial cells [11]. Blocking the effects of VEGF on endothelial cells by re-
ceptor antagonists [12–14] or neutralizing anti-VEGF antibodies
[15,16] inhibits the expansion of a variety of neoplasms. However, there
is recent evidence that the effects of these anti-VEGF strategies seem to
be transient, in particular when the treatment is interrupted [17].
An alternative approach to destroy tumor endothelium would be a
targeted delivery of potent toxins to tumor endothelial cells. We con-
ducted in vitro and in vivo experiments to evaluate the effects of SLT-
VEGF fusion protein comprising VEGF121 and catalytically active A
subunit of Shiga-like toxin 1 (SLT-1) produced by Escherichia coli
O157:H7 [18,19]. SLT-1 is composed of a single copy of a 32-kDa
A subunit associated with a ring-shaped pentamer of 7-kDa B subunits
that bind to the cellular receptor globotriaosylceramide known as
Gb3/CD77 and enters cells through CD77-mediated endocytosis.
SLT-1 was chosen as a potential “natural killer” of endothelial cells be-
cause it is known that damage to endothelial cells caused by SLT-1
plays a causative role in the pathogenesis of hemorrhagic colitis and
hemolytic uremic syndrome induced by E. coli O1 57:H7 [20,21].
SLT-VEGF is internalized through VEGFR-2 mediated endocytosis,
and its cytotoxicity correlates with VEGFR-2 expression [18]. In animal
tumor models, SLT-VEGF selectively depletes VEGFR-2–overexpressing
CD31+ endothelial cells in tumor vasculature as judged by immuno-
histochemical analysis [19] and whole body imaging of VEGF receptors
[22]. In contrast, CD31+ tumor endothelial cells that express relatively
low levels of VEGFR-2 are marginally affected by SLT-VEGF [19].
The aim of this study was to evaluate a novel antiangiogenic treat-
ment strategy for pancreatic cancer by selectively damaging endothelial
cells at sites of angiogenesis with SLT-VEGF in a clinically relevant or-
thotopic nude mouse model of pancreatic cancer. In addition, we inves-
tigated whether a combination of SLT-VEGF with the cytotoxic agent
gemcitabine increases the therapeutic potential in this animal model.
As a control, we assessed the effects of SLT-VEGF on proliferation and
viability of the human pancreatic cancer cell lines AsPC-1 andHPAF-2
and the human endothelial cell line HUVEC in vitro.
Materials and Methods
Cell Line and Culture Conditions
The human pancreatic adenocarcinoma cell lines AsPC-1 (ATCC,
CRL-1682) and HPAF-2 (ATCC, CRL-1997) of ductal origin and
the noncancerous endothelial cell line HUVEC (C-12200) were ob-
tained from the American Type Culture Collection (ATCC,Manassas,
VA) and from PromoCell GmbH (Heidelberg, Germany). The cells
were cultured in RPMI-1640 medium (AsPC-1; Invitrogen, Karlsruhe,
Germany), minimum essential medium (HPAF-2; PAA, Cölbe, Ger-
many), or endothelial cell growth medium (HUVEC; PromoCell), sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS-Gold;
PAA), penicillin G (100 U/ml), streptomycin (100 μg/ml), and am-
phothericin B (0.25 mg/ml). Cells were incubated at 37°C in humidi-
fied air with 5%CO2. Themediumwas replaced twice a week, and cells
were maintained by serial passaging after treating with 0.1% trypsin.
Reverse Transcription–Polymerase Chain Reaction
Total cellular RNAwas extracted from cell cultures using the Nucleo-
Spin RNA II Kit (Macherey & Nagel, Düren, Germany) according
to the manufacturer’s instructions and resuspended in 50 μl of water
treated with 0.1% DMPC (Sigma-Aldrich, Seelze, Germany). RNA
concentration was determined using a BioPhotometer (Eppendorf
Scientific, Hamburg, Germany). Reverse transcription of total RNA
(2 μg) primed with an oligo(dT) oligonucleotide and supplemented
with dNTPs (Sigma-Aldrich) was done with M-MLV reverse transcrip-
tase (Promega, Mannheim, Germany) according to the instructions of
themanufacturer. First-strand complementary DNAwas amplified with
transcript-specific oligonucleotides using Ready-Mix Taq PCRReaction
Mix (Sigma-Aldrich).
The primers (TIB MOLBIOL, Berlin, Germany) for the respective
genes were designed as follows: VEGF, sense 5′-CGAAGTGGTGAA
GTT CAT G-3′ and antisense 5′-TTC TGT ATC AGT CTT TCC
TGG TGA G-3′; Flt1/VEGFR-1, sense 5′-GAA GGC ATG AGG
ATG AGA GC-3′ and antisense 5′-CAG GCT CAT GAA CTT GAA
AGC-3′; KDR/FLK1/VEGFR-2, sense 5′-CATGTA CGG TCTATG
CCA TTC-3′ and antisense 5′-CGT TGG CGC ACT CTT CCT-3′;
and β-actin, sense 5′-TTC CTG GGC ATG GAG TCC TGT GG-3′
and antisense 5′-CGC CTA GAA GCATTT GCG GTG G-3′.
Polymerase chain reaction (PCR) products and a 100-bp DNA
molecular weight marker were analyzed by electrophoresis on a 1% aga-
rose gel. The gel was then visualized and photographed under ultra-
violet light.
SLT-VEGF Fusion Protein
SLT-VEGF fusion protein was constructed, expressed in E. coli strain
Origami(DE3)pLysS (Novagen, Madison, WI), purified, and exten-
sively characterized in vitro and in vivo as described elsewhere
[18,19,22]. SLT-VEGF retained physical integrity and functional activ-
ity after 2 hours of incubation inmurine serum at 37°C (Supplementary
Material and Figure W1). However, SLT-VEGF was inactivated by
conjugation of a single fluorescent dye (Supplementary Material and
FigureW2). For in vitro assays and intraperitoneal injection, SLT-VEGF
was dissolved in 0.9% NaCl (pH 7.5). Further dilutions for in vitro
studies were made with medium and filtered before use.
In Vitro Assessment of Cell Proliferation and Viability
To examine the effect of SLT-VEGFon in vitro cell proliferation, 2 ×
105 cells from the human pancreatic cancer cell lines AsPC-1, HPAF-2,
and the noncancerous human endothelial cell lineHUVECwere seeded
in six-well culture plates in 2 ml of the respective cell culture medium.
The medium was changed the next day (day 1) and SLT-VEGF (0.1-
10 nM) was added. After 72 hours (day 4), the cells were trypsinized
and counted in a standard hemocytometer. Cell viability was assessed
by a colorimetric dye reduction assay with monotetrazolium (MTT;
Boehringer,Mannheim, Germany) according to themanufacturer’s in-
structions. Briefly, cells were seeded in 96-well plates at a density of
5 × 103 cells per well in 0.2 ml of the respective medium. Medium was
changed the next day (day 1), and SLT-VEGF (0.1-10 nM) was added
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to triplicate wells. After 72 hours (day 4), 10 μl of MTT (5 mg/ml)
solution, and after additional 4 hours of incubation at 37°C 10%,
SDS was added to the cells, 100 μl per well. The plates were allowed
to stand overnight (37°C at 5%CO2). The change in absorbance mea-
sured at 550 nm with a plate reader (Biotek Instruments, Inc, Burling-
ton, VT) has been shown to strongly correlate with the number of
viable cells. All experiments were generated in triplicates and repeated
three times.
In Vitro Capillary Tube Formation Assay
The ability of SLT-VEGF fusion protein to inhibit angiogenesis
in vitrowas evaluated in a capillary tube formation assay usingHUVECs
cultured on a synthetic basement membrane matrix. Under these con-
ditions, HUVECs are capable of morphologic differentiation into an
extensive network of capillary-like structures composed of highly or-
ganized three-dimensional cords [23]. The 96-well cell culture plates
were coated with a 100-μl layer of the synthetic basement mem-
brane substrate Matrigel (Becton Dickinson, Heidelberg, Germany)
at 10 mg/ml concentration and were incubated at 37°C for 30 minutes
to promote gelling.HUVECs were seeded in coated plates, 1.8 × 104 cells
per well, SLT-VEGF fusion protein was diluted in cell medium and added
to HUVECs in triplicate wells to final concentrations of 1 or 10 nM.
Stimulation with VEGF (250 pg/ml) served as positive control. After
an 18-hour incubation at 37°C and 5% CO2 humidified atmosphere,
the complete capillary tube network within a designated area of a low
magnification (×10) field was counted under light microscopy, and
data were expressed as percentage of complete capillary tube formation
relative to untreated HUVEC control cultures incubated under the
same conditions. The assays were done in triplicates in three indepen-
dent experiments.
Orthotopic Nude Mouse Model of Pancreatic Cancer
We used the transplantation technique previously described for an
orthotopic nude mouse and rat model of pancreatic cancer [24,25].
Four-week-old male nude mice were obtained from Charles River
Laboratories (Charles River, Sulzfeld, Germany). Donor mice were
anesthetized with isoflurane (Forene; Abbott, Wiesbaden, Germany)
inhalation. Ten million cells of either the AsPC-1 or HPAF-2 cell line
were injected subcutaneously into the animals’ flanks. The animals
were killed by a lethal dose of isoflurane inhalation and opening of
the thorax after 4 weeks, when the subcutaneous tumors had reached a
size of 1 cm in largest diameter. The donor tumors were harvested and
minced by a scalpel (no. 11) into small (1 mm3) fragments. Tumor re-
cipient nude mice were anesthetized with isoflurane, followed by in-
traperitoneal injection of xylazine hydrochloride (Rompun, 12 mg/kg
body weight [BW]; Bayer, Leverkusen, Germany) and Esketamin-
hydrochloride (Ketanest S, 40 mg/kg BW; Parke-Davis/Pfizer, Karlsruhe,
Germany). The animals’ abdomens were opened by a midline incision,
and the pancreatic tail with the spleen was gently exteriorized. Two small
tissue pockets were prepared in the pancreatic parenchyma as an implan-
tation bed with a microscissor (RS-5610 VANNAS; Roboz, Rockville,
MD). One donor tumor fragment was placed into each pancreatic
tissue pocket in such a way that the neoplastic tissue was completely
surrounded by pancreatic parenchyma. The pancreas was relocated
into the abdominal cavity, which was then closed in two layers with
4-0 absorbable suture (Vicryl, Ethicon, Germany). For pain relief, a
subcutaneous injection of carprofen (Rimadyl, 4 mg/kg BW; Pfizer)
was given after surgery.
In Vivo Treatment with SLT-VEGF and Gemcitabine
The animals were allocated randomly into four treatment groups
(SLT-VEGF, prophylaxis and therapy; SLT-VEGF and gemcitabine,
prophylaxis and therapy) and one control group. Administration of SLT-
VEGF (200 μg/kg, intraperitoneally every second day), of gemcitabine
(125mg/kg, intraperitoneally once a week), as well as the combination of
both substances began either 3 days (prophylaxis) or 6 weeks (therapy)
after tumor induction. Control animals received equivalent amounts
of saline. The therapy was continued up to 14 weeks after tumor
induction.
Quantification of Tumor Growth and Spread
All animals underwent autopsy after 14 weeks after the orthotopic
tumor implantation by a lethal dose of isoflurane. The perpendicular
diameters of the primary orthotopic tumor were measured with cal-
ipers, and the volume was calculated using the following formula:
volume = length × width × depth / 2. A dissemination score was used
to assess local tumor infiltration as well as distant metastasis [24,25]. Lo-
cal infiltration was determined at the following sites: spleen, stomach,
liver (hilus), kidney, retroperitoneum, diaphragm, mesentery, bowel
loops, and abdominal wall. Isolated tumor nodules with no anatomic
connection to the primary tumor were considered distant metastases.
The sites of evaluation included liver, kidney, spleen, lung, diaphragm,
mesentery, retroperitoneum, mediastinum, and the suture line. Tumor
dissemination was quantified as follows. Each manifestation of tumor
infiltration or metastasis was credited with one point. Additional points
were awarded for massive local infiltration (e.g., including more than
half of the circumference of the spleen), multiple metastatic nodules
(>1 in parenchymal organs; >10 in diaphragm, mesentery, and retro-
peritoneum), and metastatic nodules more than 50 mm3. Clinical con-
sequences of tumor growth were incorporated into the following scoring
system: formation of ascites (2 points if volume > 5ml), development of
jaundice, ileus, and cachexia. The primary tumor and all sites of poten-
tial infiltration or metastasis were harvested, fixed in 4% formaldehyde,
and embedded in paraffin. Then 3-μm-thick tissue sections were ob-
tained and stained with hematoxylin and eosin for microscopic exam-
ination. The sections were reviewed to confirm the findings of the
macroscopic dissemination score.
Immunohistochemistry
Immunohistochemical staining was performed on paraffin-embedded
tissue of the collected primary tumor tissue. Three-micrometer-thick
sections were cut, using a rotation microtome (RM2125RT; Leica,
Wetzlar, Germany). The sections were deparaffinized in xylene and re-
hydrated in graded alcohols and distilled water. After antigen retrieval
with 0.01% EDTA pH 8.0, endogenous peroxidase activity was
blocked with 1% hydrogen peroxide in distilled water for 25 minutes
followed by washing with distilled water and finally PBS + 0.1% Tween
for 5 minutes. To bind nonspecific antigens, the sections were incu-
bated with 1× Power Block (BioGenex, San Ramon, CA) for 5 minutes.
The primary antibodies were purified antirabbit CD-31 (platelet endo-
thelial cell adhesion molecule), VEGF, VEGFR-1, and VEGFR-2 pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
diluted 1:100 to 1:150 in antibody diluent (DCS LabLine, Hamburg,
Germany) were applied to tissue sections and incubated for 30minutes
at 37°C. As a negative control, sections were incubated with antibody
diluent instead of the primary antibody. This was followed by incuba-
tion with biotinylated antirabbit immunoglobulin G (1:200; Santa
Cruz Biotechnology) for 30 minutes at 37°C. After washing with
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PBS + Tween-20 and incubating with peroxidase-conjugated avidin-
biotin complexes (KPL, Gaithersburg, MD), the immune complexes
were visualized by 3,3′-diaminobenzidine (Sigma-Aldrich). The sec-
tions were then counterstained with Mayer hematoxylin, upgraded
alcohols, mounted, and analyzed by standard light microscopy.
Microvessel Density
Anti-CD31 was used as an endothelial marker to highlight intra-
tumoral microvessels. Microvessel density (MVD) was quantified as
described by Weidner [26]. Areas of highest neovascularization were
found by scanning the sections at a magnification of ×100, and in-
dividual microvessel counts were made on 10 fields at ×200 magni-
fication (≈0.74 mm2 per field).
Statistical Analysis
All results are presented as mean ± SEM. Continuous normally
distributed variables were analyzed by the Student’s t test. Discontin-
uous variables (dissemination score and MVD) were analyzed by the
Mann-Whitney rank sum test. Differences in survival were tested by
the χ 2 test. P < .05 was considered as statistically significant.
Results
In Vitro
Messenger RNA expression of VEGF and its receptors in human
pancreatic cancer cell lines. Expression of VEGF, Flt1/VEGFR-1
and KDR/FLK1/VEGFR-2 messenger RNA (mRNA) in the human
pancreatic cancer cell lines AsPC-1 andHPAF-2 as well as in the human
endothelial cell line HUVEC were determined with reverse transcrip-
tion (RT)–PCR (Figure 1). All three cell lines exhibited both VEGF
(400 bp) and Flt1/VEGFR-1 (300 bp) transcripts.OnlyHUVECswere
positive for KDR/FLK1/VEGFR-2 (200 bp).
Effect of SLT-VEGF on proliferation and cell viability. The effect
of SLT-VEGF on the proliferation and viability of the human pancre-
atic cell lines AsPC-1, HPAF-2, and the noncancerous human endo-
thelial cell line HUVEC was studied during a period of 72 hours.
HUVECs express relatively low numbers of VEGFR-2/cell (∼10-
25,000) and therefore were not expected to be particularly sensitive
to toxin-VEGF fusion proteins, as its cytotoxicity of such proteins
strongly depends on the VEGFR-2 density in targeted cells [18,27].
The fusion protein was applied to the cells at three different final con-
centrations: 0.1, 1, and 10 nM. Figure 2 shows proliferation and via-
bility changes during the treatment. Cell count and an MTT-assay
indicate that SLT-VEGF did not influence proliferation of pancreatic
cancer cells significantly, even at the highest concentrations (10 nM).
Proliferation of the human endothelial cell line HUVEC decreased
significantly by 37% in cell count (P < .001); however, viability of
HUVEC detected by an MTT-based assay was only marginally af-
fected (approximately 10%) and only at the highest SLT-VEGF
concentration.
Capillary tube formation assay. The biologic activity of SLT-VEGF
was evaluated in an in vitro bioassay of angiogenesis. TheHUVEC cap-
illary tube formation assay on a Matrigel synthetic basement membrane
is a widely used in vitro system to model effectively the distinct temporal
and spatial events underlying angiogenesis in vivo [28]. SLT-VEGF
Figure 1. Expression of VEGF and its receptors Flt/VEGFR-1 andKDR/
FLK1/VEGFR-2 in human pancreatic cancer cell lines (AsPC-1 and
HPAF-2) and HUVEC endothelial cells measured by RT-PCR. VEGF
and Flt/VEGFR-1 mRNA was detectable in all three cell lines, but
KDR/FLK1/VEGFR-2 mRNA was only present in the endothelial cell
line HUVEC.
Figure 2. (A) In vitro effects of SLT-VEGF on proliferation of AsPC-1,
HPAF-2, and HUVECs as assessed by cell count after 72 hours of
incubation. Increased concentrations of SLT-VEGF inhibited prolif-
eration of the human endothelial cell line HUVEC (*P< .001). Prolif-
eration of the pancreatic cancer cell lines AsPC-1 and HPAF-2 was
not affected. (B) In vitro effects of SLT-VEGF on viability of AsPC-1,
HPAF-2, and HUVECs as assessed by MTT assay after 72 hours of
incubation. Even at high concentrations of SLT-VEGF (10 nM), viabil-
ity of pancreatic cancer cells and endothelial cells was consistent.
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displayed statistically significant dose-related inhibition of complete
HUVEC capillary tube formation. VEGF-induced capillary tube for-
mation was inhibited by 24.3% at 1 nM and by 50.8% at 10 nM SLT-
VEGF. Exogenous stimulation with VEGF significantly increased
HUVEC tube formation (Figure 3).
In Vivo
Volumes of primary tumors. All control animals developed extensive
tumor growth (AsPC-1: 1550 ± 131 mm3; HPAF-2: 3920 ± 184 mm3),
whereas there was significantly reduced tumor growth in the SLT-VEGF
and gemcitabine monotherapy groups and in SLT-VEGF plus gem-
citabine combination group. For tumors derived from poorly differen-
tiated AsPC-1 cells, treatment with SLT-VEGF resulted in a reduced
tumor volume of 487 ± 56 mm3 (−69%) in the prophylaxis group and
492 ± 72mm3 (−68% reduction) in the therapy group. Treatment with
gemcitabine was somewhat less effective and reduced the volume of
AsPC-1 tumors to 678 ± 115 mm3 (−56% reduction) in the prophy-
laxis group and to 928 ± 491 mm3 (−40% reduction) in the therapy
group. However, the combination of SLT-VEGFwith gemcitabine was
significantly most effective in AsPC-1 tumors than either monotherapy
and inhibited primary tumor growth to 177 ± 31 mm3 (−89% reduc-
tion) in the prophylaxis group and to 360 ± 76 mm3 (−77% reduction)
in the therapy group (Figure 4A).
Tumors derived from the moderately differentiated HPAF-2 cells were
reduced by SLT-VEGF treatment to 1069 ± 267mm3 (−73% reduction)
in the prophylaxis group and to 1587 ± 167mm3 (−60% reduction) in
the therapy group. Treatment with gemcitabine was significantly more
effective and diminished tumor growth of the HPAF-2 tumors to 184 ±
133 mm3 (−95% reduction) in the prophylaxis group and to 361 ±
284 mm3 (−91% reduction) in the therapy group. Interestingly, com-
bination of both substances did not prove to be more effective than
gemcitabine alone and reduced tumor growth of HPAF-2 tumors to
178 ± 204 mm3 (−95% reduction) in the prophylaxis group and to
711 ± 270mm3 (−82% reduction) in the treatment group (Figure 4A).
Tumor dissemination. Local infiltration and distant metastasis
were summarized by a dissemination score. Control animals with tu-
mors derived from the poorly differentiated AsPC-1 cell line reached
a high score (20.4 ± 2.5 points). Treatment with SLT-VEGF tended to
result in a reduction of tumor spread to 13.2 ± 2.4 points in the pro-
phylaxis group and was not effective (18.6 ± 2.0 points) in the therapy
group. Animals treated with gemcitabine showed no difference in tumor
spread in comparison to control animals (22.6 ± 4.2 points, prophylaxis
group; 23.7 ± 9.2 points, therapy group). Combined treatment with
SLT-VEGFand gemcitabine resulted in a significant reduction of tumor
dissemination in animals with AsPC-1 tumors in the prophylaxis group
(8.0 ± 1.1 points) and in the therapy group (9.8 ± 2.4 points; Figure 4B).
Tumors derived from the HPAF-2 cell line also displayed a high dis-
semination score (17.0 ± 1.2 points). Administration of SLT-VEGF
reduced tumor spread to 10.4 ± 2.2 points in the prophylaxis group
but not in the therapy group (15.9 ± 2.7 points). Treatment with gem-
citabine inhibited tumor dissemination significantly to 1.2 ± 1.0 points
in the prophylaxis group and to 3.4 ± 1.5 points in the therapy group.
Tumor spread was almost completely suppressed after combined
treatment with SLT-VEGF and gemcitabine in the prophylaxis group
(0.58 ± 1.2 points) and significantly reduced in the therapy group (4.4 ±
2.3 points; Figure 4B).
Survival. The AsPC-1 tumors showed a relative aggressive behavior
in vivo, which was reflected in a low 14-week survival of the controls
(17%).Monotherapy with SLT-VEGF revealed a trend to increase sur-
vival rates in the therapy group (25%) and increased 14-week survival in
the prophylaxis group to 75% (P < .05). Treatment with gemcitabine
resulted in an increase of survival rates to 58% in both therapy and pro-
phylaxis groups. Combination of SLT-VEGF with gemcitabine revealed
a tendency toward increased 14-week survival in the therapy (58%) and
the prophylaxis groups (83%; Figure 4C ).
Tumors derived from the HPAF-2 tumors grew less aggressively
than AsPC-1 tumors and resulted in higher 14-week survival (33%
vs 17%). Monotherapy with SLT-VEGF increased survival to 75% in
the therapy group and 83% in prophylaxis group. Gemcitabine alone
led to an increased survival of 83% in the therapy group and of 92%
in the prophylaxis group. The combined treatment of SLT-VEGF and
gemcitabine resulted in a 100% survival in both (therapy and prophy-
laxis) groups (Figure 4C).
Microvessel density. As a parameter of angiogenic activity, MVD
was determined by immunohistochemistry using anti-CD31 as an
endothelial marker. MVD was enhanced 4.6- and 5.3-fold in the
Figure 3. Dose-related effect of SLT-VEGF on capillary tube forma-
tion of HUVEC after 18 hours of incubation on Matrigel basement
membrane; stimulation with VEGF served as positive control. Com-
plete capillary tube networks within a designated area were
counted under light microscopy (magnification, ×10), and the data
were expressed as percentage inhibition of complete capillary tube
formation relative to untreated HUVEC control cultures incubated
under the same conditions. Photomicrographs (×100) of HUVEC
capillary tube formation in untreated cultures (A), 250 pg/ml VEGF
(B), 1 nM SLT-VEGF (C), and 10 nM SLT-VEGF (D); *P < .05 versus
control, respectively.
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untreated AsPC-1 and HPAF-2 primary tumors, respectively, compared
with normal exocrine pancreas (AsPC-1, 70.0 ± 4.3/0.74 mm2; HPAF-2,
80.5 ± 4.3/0.74 mm2; native pancreas, 15.6 ± 1.5/0.74 mm2; P < .001).
Treatment with SLT-VEGF significantly reduced MVD of AsPC-1
primary tumors in the prophylaxis group (40.8 ± 4.3/0.74 mm2)
and in the therapy group (48.9 ± 6.1/0.74 mm2). Administration
of gemcitabine resulted in a reduced MVD in animals of the prophy-
laxis group (56.1 ± 3.3/0.74 mm2) as well as in the therapy group
(54.0 ± 18.7/0.74 mm2). Combined treatment with SLT-VEGF and
gemcitabine showed no additional benefit in reducing MVD (46.0 ±
6.1/0.74 mm2 prophylaxis group; 52.2 ± 6.3/0.74 mm2 therapy
group; Figure 5, A-C ).
In animals with HPAF-2 tumors, treatment with SLT-VEGF resulted
in a significant reduction ofMVD in both groups (45.9 ± 3.5/0.74mm2,
prophylaxis; 49.3 ± 3.5/0.74 mm2, therapy). Monotherapy with gemci-
tabine reduced MVD in the prophylaxis group (57.0 ± 2.4/0.74 mm2)
and the therapy group (46.3 ± 11.7/0.74 mm2). Combination of SLT-
VEGF and gemcitabine resulted in no further reduction of MVD in
the prophylaxis group (50.8 ± 14.3/0.74 mm2) and in the therapy group
(60.3 ± 4.6/0.74 mm2; Figure 5, A, B, and D).
Immunohistochemical analysis of VEGF and its receptors. To de-
termine the immunohistochemical localization of VEGF and its re-
ceptors Flt1/VEGFR-1 and KDR/FLK1/VEGFR-2, highly specific
polyclonal antibodies were used. Moderate to strong VEGF immuno-
reactivity was found in the cytoplasm of pancreatic cancer cells of
AsPC-1 and HPAF-2 tumors (Figure 6, A and B). Both cell lines were
also mildly to moderately immunoreactive for VEGFR-1 but not for
VEGFR-2 (Figure 6, C-F ). VEGFR-2 was only detected in endothelial
cells of the tumors (Figure 6, G and H ).
Figure 4. Orthotopic pancreatic cancerwas derived frompoorly differentiatedAsPC-1 andmoderately differentiatedHPAF-2 cells. Treatment
started after either 3 days (prophylaxis) or 6 weeks (therapy) and was continued up to 14 weeks. (A) Volume of the primary tumor in control
mice and animals treatedwith SLT-VEGF, gemcitabine, or the combination therapy. Images are representative of primary tumors derived from
AsPC-1 cancer cells (control, after prophylactic SLT-VEGF treatment, after therapeutic SLT-VEGF treatment). (B) Dissemination scores, quan-
tifying local and distant tumor spread, in control mice and animals treated with SLT-VEGF, gemcitabine, or the combination therapy. Images
are representative for livermetastasis; primary tumorswerederived fromAsPC-1cancer cells (control, after prophylacticSLT-VEGF treatment,
after therapeutic SLT-VEGF treatment). (C) Fourteen-week survival in control mice and animals treated with SLT-VEGF, gemcitabine, or the
combination therapy.
Figure 5. MVD in primary tumors of controls and animals treated with SLT-VEGF, gemcitabine, or the combination therapy was deter-
mined by immunohistochemistry for CD31 (A, prophylactic treatment; B, therapeutic treatment). Primary tumors were derived from the
cell lines AsPC-1 (C, control animal; magnification, ×200) and HPAF-2 (D, control animal; magnification, ×200).
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Discussion
Targeting proangiogenic mediators such as VEGF and VEGFR-2 has
emerged as a promising anticancer treatment strategy, especially for
devastating malignancies such as exocrine pancreatic cancer, which is
virtually noncurable by surgical resection and/or chemoradiation
[29,30]. Growth of primary tumor and metastatic lesions beyond
the size of a few cubic millimeters requires neovascularization that
combines angiogenesis and vasculogenesis. Therefore, inhibition of
angiogenesis is an attractive and promising target for tumor therapy
because it theoretically offers the hope of long-term control of neo-
plasm progression [3]. Kuehn et al. [8] demonstrated that MVD and
expression of proangiogenic factors such as VEGF were significantly
higher in pancreatic cancer in comparison to the normal pancreas.
The VEGF receptors are expressed at high levels in the activated en-
dothelium of tumor vasculature in general [31] and in pancreatic
cancer, specifically [32], whereas normal mature blood vessels show
negligible levels of VEGF receptors [33]. Our previous research dem-
onstrated that systemic treatment with VEGF coupled to diphtheria-
toxin (DT-VEGF) led to specific targeting and damaging of tumor
blood vessels [34].
In this study, we investigated a more specific approach: the effect
of the immunotoxin SLT-VEGF that selectively targets endothelial
cells overexpressing VEGFR-2 [17,18,22]. Using two cancer animal
models, syngeneic 4T1 murine breast cancer and PC3 human pros-
tate cancer xenografts, we have previously demonstrated that three to
five biweekly injections of SLT-VEGF fusion protein inhibited tumor
growth approximately two-fold [18]. Detailed immunohistochemical
analysis of 4T1 tumors revealed that SLT-VEGF treatment only
mildly (1- to 1.4-fold) decreases the overall prevalence of CD31+ tu-
mor endothelial cells. In contrast, the prevalence of VEGFR-2–over-
expressing tumor endothelial cells decreased four- to five-fold [19].
These findings were supported by the results of whole body imaging
Figure 6. Immunostaining (brown color) of orthotopic tumors in nude mice derived from the human pancreatic cancer cell lines AsPC-1
and HPAF-2 revealed expression of VEGF (A, B) and Flt/VEGFR-1 (C, D) in tumor cells, thereby confirming RT-PCR results (Figure 1).
Pancreatic cancer cells were negative for KDR/FLK1/VEGFR-2 (E, F) in contrast to VEGFR-2–positive endothelial cells (G, H). Magnifi-
cation, ×200.
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of VEGFR-2 in tumor vasculature with VEGF-based near-infrared
fluorescent tracers [22]. In these experiments, SLT-VEGF treatment
dramatically inhibited VEGFR-2–mediated accumulation of tracers
in tumor endothelial cells, reflecting the depletion of endothelial cells
overexpressing VEGFR-2 [22]. Taken together, in vitro and in vivo
results indicate that SLT-VEGF may be less toxic for normal endothe-
lial cells of the host organism but targets predominantly proliferating
tumor endothelial cells with reportedly upregulated expression of
VEGFR-2 [11]. Using two cancer animal models, syngeneic 4T1 mu-
rine breast cancer and PC3 human prostate cancer xenografts, we have
previously demonstrated that SLT-VEGF fusion protein inhibited tu-
mor growth by selective elimination of tumor endothelial cells express-
ing high levels of VEGFR-2 [22]. This indicates that SLT-VEGF may
be less toxic for normal endothelial cells of the host organism but tar-
gets predominantly proliferating tumor endothelial cells with reportedly
upregulated expression of VEGFR-2 [11]. Indeed, as we report here hu-
man endothelial cell line HUVEC, a model system for normal endothe-
lial cells with physiological level of VEGFR-2 expression showed a
somewhat decreased proliferation (Figure 2A) and tube formation (Fig-
ure 3) but not viability (Figure 2B). In contrast, DT-VEGFwas reported
to be cytotoxic to HUVECs [35].
The antitumor effects of SLT-VEGF were evaluated in an orthotopic
nude mouse model of pancreatic cancer, which was established in our
laboratory [24]. This model mirrors the development of this clinical dis-
ease and allows assessment not only of primary tumor growth but also
of metastasis and survival. Importantly, both pancreatic cancer cell
lines AsPC-1 and HPAF-2 used in these models were not sensitive
to SLT-VEGF (Figure 2), indicating that its therapeutic effects are
due predominantly to the sensitivity of endothelial cells. Furthermore,
in both models, selected regimens of SLT-VEGF (200 μg/kg, gemci-
tabine, or both drugs) did not exhibit any clinical evidence of toxicity,
such as a change in food intake or activity in treatment groups, com-
pared with control animals.
Poorly differentiated AsPC-1 tumors displayed an aggressive growth
pattern, killing most control animals before the end of the 14-week
observation period. SLT-VEGF treatment, started either 3 days (pro-
phylaxis group) or 6 weeks (treatment group) after tumor implantation,
reduced microvascular density in primary tumors 1.7- and 1.4-fold, re-
spectively. Remarkably, these rather modest changes in microvascular
density were associated with reduced primary tumor volume (up to
−69%), increased survival (up to +58%; Figure 4, A and C ), and de-
creased tumor dissemination in the prophylaxis group (Figure 4B).
Moderately differentiated HPAF-2 cells grew to large, partly cystic
tumors in control mice and displayed a moderate local and systemic
pattern of spread. The response to SLT-VEGF treatment was similar to
that observed in poorly differentiated AsPC-1 tumors: moderate de-
crease in microvascular density (Figure 5, A and B), rather dramatic
decrease in tumor volume and increase in survival, and inhibition of
tumor dissemination in the prophylaxis group (Figure 4B).
It is interesting to compare the effects of SLT-VEGF with those
of gemcitabine, the frontline drug for advanced pancreatic cancer.
Gemcitabine monotherapy resulted in an increased survival (AsPC-1,
up to 58%; HPAF-2, up to 92%; Figure 4C), and a decreased primary
tumor volume (Figure 4A). Tumor dissemination of AsPC-1 tumors was
almost unaffected in gemcitabine treatment group (Figure 4B). It seems
that SLT-VEGF is somewhat more effective in inhibiting tumor growth
and metastatic dissemination, as well as overall survival, in the poorly
differentiated AsPC-1 model. In contrast, gemcitabine was more effec-
tive in inhibiting tumor growth and metastatic dissemination in the
moderately differentiated HPAF-2 model. Importantly, in both models,
combination of both drugs provided for a tendency toward better sur-
vival, lower primary tumor volume, and reduced tumor dissemination,
especially in the prophylaxis groups of both AsPC-1 and HPAF-2 tu-
mors (Figure 4, A-C). However, this tendency did not reach statistical
significance for all parameters. It may be due to the significant antitumor
effects of the respective monotherapies at tested regimens, especially in
theHPAF-2 group, whichwere difficult to improve by the combination.
In turn, it suggests that theremight be opportunities for decreasing doses
of each component without losing therapeutic benefits of the combina-
tion. Furthermore, these results suggest that combination of SLT-VEGF
and gemcitabine might require careful optimization to reach the most
advantageous synergy. For example, because SLT-VEGF is more cyto-
toxic to cells overexpressing VEGFR-2, treatment with this cytotoxin
might be more effective if timed to the stages when tumor vasculature
is enriched with such cells, for example, in response to treatment with
other drugs.
Interestingly, SLT-VEGF and gemcitabine induced rather similar
decreases in microvascular density in both tumor models. SLT-VEGF
targets tumor endothelial cells overexpressing VEGFR-2, selectively
depleting tumor vasculature of such cells [19]. However, gemcita-
bine, a fluorinated analog of deoxycytidine, is toxic to proliferating
endothelial cells because it inhibits DNA replication either directly or
indirectly through inactivation of the RNA reductase. Thus, if actively
growing tumor endothelial cells overexpress VEGFR-2, they would be
targets for both SLT-VEGF and gemcitabine, and both drugs might
lead to similar decreases in microvascular density.
In summary, this study adds further evidence that angiogenesis is a
critical component of pancreatic cancer growth and metastasis. Cur-
rently, there are multiple clinical trials in progress for combination of
antiangiogenic drugs, such as bevacizumab, sunitinib, or sorafenib, with
chemotherapeutic agents, such as gemcitabine (www.cilicaltrials.gov).
Although there is no definitive model for combination of antiangiogenic
and chemotherapeutic drugs, there are suggestions that delivery of che-
motherapeutics to tumor cellsmight bemore efficient when provided by
tumor vasculature responding to antiangiogenic treatment. It remains to
be established whether such improved delivery takes place and whether
it is associated with “normalization” of tumor vasculature [36] or with
continuous revascularization of tumors in response to drugs, particularly
those delivered through metronomic scheduling [37]. However, regard-
less of mechanism, it seems that pancreatic cancers are sensitive to com-
binations of chemotherapeutic and antiangiogenic drugs. In this respect,
our finding that targeting VEGFR-2–overexpressing tumor endothelial
cells with SLT-VEGF fusion protein resulted in a significant biologic
improvement in two clinically relevant orthotopic pancreatic tumor
models, comparable to that induced by gemcitabine, seems particularly
significant.We believe that optimization of the SLT-VEGF/gemcitabine
regimen provides a promising treatment strategy for advanced pan-
creatic cancer.
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Supplementary Material
Stability of SLT-VEGF
SLT-VEGF stability in PBS andmurine serumwas assessed after 2 hours
of incubation at 37°C. Western blot analysis was used to assess physical
integrity, and cytotoxicity assay was used to assess functional activity.
Figure W1. (A) SLT-VEGF remains stable in PBS and serum after a
2-hour incubation at 37°C. Murine serumwas collected as described
[19] and stored frozen at −20°C in small aliquots until needed. SLT-
VEGFwas added tomurine serum (or PBS) to a final concentration of
1 μM and incubated at 37°C. Protein samples collected after 45 min-
utes and 2 hours of incubation were separated by reducing 12.5%
SDS-PAGE gel and analyzed by Western blot analysis using a rabbit
VEGF-specific antibody A-20 (Santa Cruz Biotechnology) followed
by antirabbit–HRP conjugate (GE Healthcare, Waukesha, WI). M in-
dicates molecular weight markers. (B) SLT-VEGF retains cytotoxic
activity after a 2-hour incubation at 37°C in murine serum. The cyto-
toxicity assay is described in Backer et al. [18]. Briefly, 293/KDR cells
(SibTech, Inc, Brookfield, CT) expressing 2 × 106 VEGFR-2 per cell
were seeded onto 96-well plates at a density of 2× 103 cells perwell,
in 0.05 ml of Dulbecco’s modified Eagle medium complete per well.
Twenty hours later, SLT-VEGF incubated in complete murine serum
for 2 hours at 37°C, or freshly thawed control SLT-VEGF, were serially
diluted in Dulbecco’s modified Eagle medium complete and added to
cells in triplicate wells, 0.05ml/well, tomake the final volume of 0.1ml
per well at the indicated SLT-VEGF concentrations. After 96 hours of
incubation under normal culture conditions, viable cells were deter-
mined by CellTiter 96 AQueous One Solution Cell Proliferation Assay
kit (Promega, Madison, WI). The assay was done in triplicate.
Figure W2. Directmodificationwith a fluorescent dye dramatically reduces the
functional activity of SLT-VEGF. Preparation of SLT-VEGF/Cy5 conjugate. In a se-
ries of pilot experiments, we optimized conditions ofmodification to obtain fluo-
rescent SLT-VEGF with no more than one molecule of Cy5 dye per SLT-VEGF.
The selected conditions were as follows: 43 nmol of SLT-VEGFwasmixed with
Cy5-NHS (GE Healthcare) in 0.1 M NaPi buffer of pH 7.2, to a final molar ratio of
four NHS groups per one SLT-VEGF protein. After 1 hour of incubation at room
temperature, unreacted NHSwas quenched by addition of 1:10 vol./vol. part of
1 M Tris-HCl pH 8.0 and incubation for 30 minutes at room temperature. Mod-
ified protein was purified by a combination of ion exchange chromatography
on Q-Sepharose FF (1-ml prepacked columns; GE Healthcare) and gel filtration
(PD-10 columns; GE Healthcare). Purified SLT-VEGF/Cy5 was analyzed reverse
phase high-performance liquid chromatography profile on C4 Alltech Macro-
sphere column (Alltech, Iselin, NJ). The extent of SLT-VEGF modification was
determined by analysis of peak intensities at 216 nm, for protein, and 598 nm,
for Cy5 (Backer 2007). RP HPLC analysis revealed that purified SLT-VEGF/Cy5
contained one molecule of Cy5 dye per protein. Two assays, cytotoxicity and
induction of VEGFR-2 tyrosine phosphorylation, were used to assess the func-
tional activity of SLT-VEGF/Cy5. In both assays, SLT-VEGF/Cy5 was dramatically
less active than parental SLT-VEGF, indicating that conjugating even a singleCy5
per SLT-VEGF dramatically decreases the ability of protein to bind to VEGFR-2
and become internalized via VEGFR-2–mediated endocytosis. (A) Cytotoxicity
of SLT-VEGF/Cy5 is dramatically decreased. The cytotoxicity of SLT-VEGF/Cy5
was tested using 293/KDR cells, as described [18] (see also FigureW1B). In this
assay, 50% inhibition of cell growthwas not reached at 5 nMSLT-VEGF/Cy5, as
opposed to the IC50 value of 0.1 nM for parental SLT-VEGF (FigureW1A). (B) The
ability of SLT-VEGF/Cy5 to activate VEGFR-2 is dramatically reduced. The
reduced cytotoxicity of SLT-VEGF/Cy5 might be a result of either damaged en-
zymatic activity of the SLT moiety or the reduced ability of the VEGF moiety to
bind to VEGFR-2 and deliver the fusion protein inside the cell through receptor-
mediated internalization. To assess the ability of SLT-VEGF/Cy5 to bind to and
activate VEGFR-2, we used induction of VEGFR-2 tyrosine phosphorylation in
293/KDR cells assay (as described in Backer and Backer [18]). Briefly, near-
confluent 293/KDR cells after overnight starvation were stimulated with varying
amounts of SLT-VEGF or fluorescent SLT-VEGF/Cy5, for 10minutes at 37°C and
then lysed and analyzed by Western blot analysis using anti-phosphotyrosine
antibody PT-66 (Sigma, St Louis, MO). Arrows indicate the position of VEGFR-2.
pY indicates phosphotyrosine. Note that VEGFR-2 tyrosine phosphorylation is
dramatically lower on stimulation with SLT-VEGF/Cy5, as opposed to parental
SLT-VEGF protein. These results indicate that conjugation of a single Cy5 dye
toSLT-VEGF resulted inmodificationof lysine residues ofVEGFmoiety that are
critically involved in the interaction of VEGFmoiety with its receptor, VEGFR-2.
